Glucocorticoid bioactivity does not predict response to steroid therapy in severe pediatric ulcerative colitis

Inflammatory Bowel Diseases

Volumn 16, Issue 3, 2010, Pages 469-473

  Turner, Dan ^a   Kolho, Kaija Leena ^b   Mack, David R ^c   Raivio, Taneli ^b   Leleiko, Neal ^d   Crandall, Wallace ^e   Markowitz, James ^f   Silverberg, Mark S ^g   Jänne, Olli A ^b   Stempak, Joanne ^g   Hyams, Jeffrey ^h   Griffiths, Anne M ⁱ  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF HELSINKI   (Finland)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d BROWN UNIVERSITY   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^g MOUNT SINAI HOSPITAL   (Canada)

^h UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Bioavailability; Children; Corticosteroids; Glucocorticoid bioassay; Hospitalization; Outcome; Ulcerative colitis

Indexed keywords

HYDROCORTISONE; INFLIXIMAB; METHYLPREDNISOLONE; PREDNISONE;

ADOLESCENT; ADULT; ANIMAL CELL; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COLON RESECTION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MULTICENTER STUDY; NONHUMAN; PHLEBOTOMY; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADOLESCENT; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL ASSAY; CERCOPITHECUS AETHIOPS; CHILD; COLECTOMY; COLITIS, ULCERATIVE; COS CELLS; DRUG MONITORING; FEMALE; GLUCOCORTICOIDS; HOSPITALIZATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS;

EID: 77149159512     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21070     Document Type: Article

References (28)

1. Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955;1041-1048.
2. Truelove SC, Jewell DP. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet. 1974;1:1067-1070.
3. Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. J Endocrinol. 2003;179:301-310.
4. Leung DY, Bloom JW. Update on glucocorticoid action and resistance. J Allergy Clin Immunol. 2003;111:3-22; quiz 3.
5. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007;5:103-110.
6. Turner D, Walsh CM, Benchimol EI, et al. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut. 2008;57:331-338.
7. Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003;178:339-346.
8. Kajantie E, Raivio T, Janne OA, et al. Circulating glucocorticoid bioactivity in the preterm newborn after antenatal betamethasone treatment. J Clin Endocrinol Metab. 2004;89:3999-4003.
9. Raivio T, Palvimo JJ, Kannisto S, et al. Transactivation assay for determination of glucocorticoid bioactivity in human serum. J Clin Endocrinol Metab. 2002;87:3740-3744.
10. Turner D, Mack DR, Uusoue K, Hyams JS, Leleiko N, Leach S, Walters TD, Day AS, Crandall W, Markowitz J, Silverberg MS, Otley AR, Mamula P, Griffiths AM. Prospective multicenter study of outcomes and predictors of response in severe pediatric ulcerative colitis. Gastroenterology. 2009;136(5 Suppl 1):A-571 (Abst T1745).
11. Schachter H, Kirsner JB. Definitions of inflammatory bowel disease of unknown etiology. Gastroenterology. 1975;68:591-600.
12. Turner D, Otley AR, Mack D, et al. Development and evaluation of a Pediatric Ulcerative Colitis Activity Index: a prospective multicenter study. Gastroenterology. 2007;133:423-432.
13. Turner D, Hyams J, Markowitz J, et al. Appraisal of the Pediatric Ulcerative Colitis Activity Index (PUCAI). Inflamm Bowel Dis. 2009; (in press).
14. Vihinen MK, Raivio T, Verkasalo M, et al. Circulating glucocorticoid bioactivity during peroral glucocorticoid treatment in children and adolescents with inflammatory bowel disease. J Clin Gastroenterol. 2008;42:1017-1024.
15. Berghouse LM, Elliott PR, Lennard-Jones JE, et al. Plasma prednisolone levels during intravenous therapy in acute colitis. Gut. 1982;23: 980-983.
16. Bossa F, Fiorella S, Caruso N, et al. Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol. 2007;102:601-608.
17. Rosenberg W, Ireland A, Jewell DP. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol. 1990; 12:40-41.
18. Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol. 1978;13:833-837.
19. Baron JH, Connell AM, Kanaghinis TG, et al. Out-patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J. 1962;2:441-443.
20. Chikanza LC, Panayi GS. The effects of hydrocortisone on in vitro lymphocyte proliferation and interleukin-2 and -4 production in corticosteroid sensitive and resistant subjects. Eur J Clin Investig. 1993;23: 845-850.
21. Corrigan CJ, Brown PH, Barnes NC, et al. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis. 1991;144: 1016-1025.
22. Seki M, Ushiyama C, Seta N, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:823-830.
23. Hearing SD, Norman M, Smyth C, et al. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab. 1999;84:4149-4154.
24. Farrell RJ, Murphy A, Long A, et al. High multidrug resistance (Pglycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology. 2000;118:279-288.
25. Hearing SD, Norman M, Probert CS, et al. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut. 1999;45: 382-388.
26. Flood L, Lofberg R, Stierna P, et al. Glucocorticoid receptor mRNA in patients with ulcerative colitis: a study of responders and nonresponders to glucocorticosteroid therapy. Inflamm Bowel Dis. 2001;7: 202-209.
27. Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. 2006;101:110-118.
28. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(suppl A): 5-36.